Human Genome Sciences presents interim results of phase 2b trial of Albuferon with Ribavirin in patients with chronic hepatitis
David C. Stump, M.D., Executive Vice President, Drug Development, Human Genome Sciences, said, "We believe that an interferon with less frequent dosing than pegylated interferon, and with comparable safety and efficacy, would be an important therapeutic option for patients with chronic hepatitis C. Albuferon appears capable of meeting this target at doses of 900-1200 mcg at two-week intervals."
Albuferon is a novel, long-acting form of interferon alpha 2b. It is a Human Genome Sciences drug made possible by the company's proprietary albumin fusion technology, which was used to improve the pharmacological properties of interferon alpha. Recombinant interferon alpha is approved for the treatment of hepatitis C, hepatitis B and a broad range of cancers. Human Genome Sciences is developing Albuferon for use in the treatment of chronic hepatitis C.
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.